| Literature DB >> 22587829 |
Elke Hausner1, Siw Waffenschmidt, Thomas Kaiser, Michael Simon.
Abstract
BACKGROUND: Over the past few years, information retrieval has become more and more professionalized, and information specialists are considered full members of a research team conducting systematic reviews. Research groups preparing systematic reviews and clinical practice guidelines have been the driving force in the development of search strategies, but open questions remain regarding the transparency of the development process and the available resources. An empirically guided approach to the development of a search strategy provides a way to increase transparency and efficiency.Entities:
Mesh:
Year: 2012 PMID: 22587829 PMCID: PMC3351720 DOI: 10.1186/2046-4053-1-19
Source DB: PubMed Journal: Syst Rev ISSN: 2046-4053
Cochrane Library search strategya
| ID | Search | Total hits |
|---|---|---|
| #1 | (brachytherapy AND prostate):ti,ab,kw | 124 |
| #2 | (#1) | 26 |
a Wiley search date 10 May 2011.
Figure 1Flowchart of an objectively derived approach using the example 'Brachytherapy in patients with prostate cancer'.
Text words after analysis with the Text Mining Package in R (extract)
| Terms | Frequency | Frequency | Sensitivity | Sensitivity |
|---|---|---|---|---|
| Patients | 25 | 1,419 | 1.0000 | 0.1976 |
| Results | 25 | 1,425 | 1.0000 | 0.1985 |
| Cancer | 24 | 361 | 0.9600 | 0.0503 |
| Methods | 24 | 335 | 0.9600 | 0.0467 |
| Prostate | 24 | 49 | 0.9600 | 0.0068 |
| Treatment | 21 | 941 | 0.8400 | 0.1311 |
| External | 20 | 86 | 0.8000 | 0.0120 |
| Therapy | 20 | 342 | 0.8000 | 0.0476 |
| Treated | 20 | 371 | 0.8000 | 0.0517 |
| Beam | 19 | 32 | 0.7600 | 0.0045 |
| Brachytherapy | 19 | 4 | 0.7600 | 0.0006 |
| Compared | 17 | 972 | 0.6800 | 0.1354 |
| Conclusions | 17 | 41 | 0.6800 | 0.0057 |
| Follow | 16 | 49 | 0.6400 | 0.0068 |
| Prostatectomy | 16 | 11 | 0.6400 | 0.0015 |
| Radical | 16 | 52 | 0.6400 | 0.0072 |
| Respectively | 16 | 72 | 0.6400 | 0.0100 |
| Risk | 16 | 584 | 0.6400 | 0.0813 |
| Specific | 16 | 488 | 0.6400 | 0.0680 |
| Localized | 15 | 66 | 0.6000 | 0.0092 |
| Months | 15 | 259 | 0.6000 | 0.0361 |
| Purpose | 15 | 192 | 0.6000 | 0.0267 |
| Radiation | 15 | 68 | 0.6000 | 0.0095 |
| Analysis | 14 | 853 | 0.5600 | 0.1188 |
| Radiotherapy | 14 | 30 | 0.5600 | 0.0042 |
| Rates | 14 | 260 | 0.5600 | 0.0362 |
| Score | 14 | 115 | 0.5600 | 0.0160 |
| Significantly | 14 | 873 | 0.5600 | 0.1216 |
| Biochemical | 13 | 87 | 0.5200 | 0.0121 |
| Gleason | 13 | 4 | 0.5200 | 0.0006 |
| Materials | 13 | 162 | 0.5200 | 0.0226 |
| Antigen | 12 | 76 | 0.4800 | 0.0106 |
| Time | 12 | 576 | 0.4800 | 0.0802 |
| Using | 12 | 1,680 | 0.4800 | 0.2340 |
Controlled vocabulary after frequency analysis with PubMed PubReMiner (extract)
| Terms | Frequency |
|---|---|
| Humans | 23 |
| Male | 23 |
| Prostatic neoplasms | 23 |
| Aged | 20 |
| Brachytherapy | 20 |
| Middle aged | 17 |
| Prostate-specific antigen | 12 |
| Prostatectomy | 12 |
| Adenocarcinoma | 9 |
| Follow-up studies | 8 |
| Retrospective studies | 8 |
| Aged, 80 and over | 8 |
| Disease-free survival | 7 |
| Radiotherapy dosage | 6 |
| Adult | 6 |
| Neoplasm staging | 5 |
| Proportional hazards models | 5 |
| Quality of Life | 4 |
| Prospective studies | 4 |
| Radiotherapy, conformal | 4 |
| Incidence | 3 |
| SEER program | 3 |
| Iodine radioisotopes | 3 |
| Risk factors | 3 |
| Combined modality therapy | 3 |
| Risk assessment | 3 |
| Survival rate | 3 |
| Treatment outcome | 3 |
| Multivariate analysis | 3 |
| Questionnaires | 3 |
Candidate terms (sorted)
| Category | Candidate terms |
|---|---|
| Health condition | |
| Prostatic neoplasms | Controlled vocabulary |
| Prostate | Text terms |
| Adenocarcinoma | Text terms |
| Cancer | Text terms |
| Intervention | |
| Brachytherapy | Controlled vocabulary |
| Brachytherapy | Text terms |
| Seed | Text terms |
| Permanent | Text terms |
| Implantation | Text terms |
| Questionable terms | |
| Iodine radioisotopes | Controlled vocabulary |
| Prostate-specific antigen | Controlled vocabulary |
| Localized | Text terms |
| Gleason | Text terms |
| PSA | Text terms |
MEDLINE search strategy (prefinal)a
| Number | Searches | Results |
|---|---|---|
| 1 | Prostatic Neoplasms/ | 78,913 |
| 2 | (prostat* and (cancer or adenocarcinoma)).ab,ti. | 73,416 |
| 3 | or/1-2 [Health condition] | 95,729 |
| 4 | Brachytherapy/ | 13,758 |
| 5 | Brachytherapy.ab,ti. | 9,822 |
| 6 | ((seed* or permanent*) and implant*).ab,ti. | 10,719 |
| 7 | or/4-6 [Intervention] | 25,031 |
| 8 | and/3,7 | 3,347 |
| 9 | ("18374503" or "11104883" or "10924979" or "15541117" or "18963536" or "15590163" or "14665356" or "9749478" or "11490252" or "18207665" or "18325680" or "19455340" or "2009027580" or "10792092" or "14697417" or "18374892" or "18801517" or "20427255" or "19570619" or "15066293" or "15737905" or "20378156" or "19670452" or "10080594" or "18538495").ui. [development set] | 25 |
| 10 | 8 and 9 | 25 |
aOvid search date 19 September 2011. Ovid MEDLINE in-process and other nonindexed references, Ovid MEDLINE daily and Ovid MEDLINE, 1950 to present.
MEDLINE validation of a search strategy with a validation seta
| Number | Searches | Results |
|---|---|---|
| 1 | Prostatic Neoplasms/ | 78,913 |
| 2 | (prostat* and (cancer or adenocarcinoma)).ab,ti. | 73,416 |
| 3 | or/1-2 [Health condition] | 95,729 |
| 4 | Brachytherapy/ | 13,758 |
| 5 | Brachytherapy.ab,ti. | 9,822 |
| 6 | ((seed* or permanent*) and implant*).ab,ti. | 10,719 |
| 7 | or/4-6 [Intervention] | 25,031 |
| 8 | and/3,7 | 3,347 |
| 9 | ("15476513" or "17293235" or "17570425" or "20399462" or "19571899" or "11597800" or "20303100" or "19376564" or "20231039" or "12084197" or "19945997" or "10758314" or "14581420").ui. [validation set] | 13 |
| 10 | 8 and 9 | 13 |
aOvid search date 19 September 2011. #1 through #8, search strategy developed; #9, search string with accession numbers of the validation set; and #10, validation of the strategy with the validation set. Ovid MEDLINE in-process and other nonindexed references, Ovid MEDLINE daily and Ovid MEDLINE 1950 to present.